|
Recent Developments |
|
24-SEP-18
Sequent Scientific has entered into a Business transfer agreement with Solara Active Pharma Sciences to acquire the EU-GMP API facility at Mahad (Mahad facility). The total consideration for the unit would be Rs 464 million on an Enterprise Valuation basis.
18-APR-18
SeQuent Scientific announced that its wholly owned subsidiary Alivira Animal Health (Alivira) through Alivira Ireland, has today signed an agreement with simultaneous cl... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Dec-2014(9) | 31-Mar-2014 (12) | 31-Mar-2013 (12) | | Net sales | 2959.04 | 4423.01 | 3132.79 | | Other Income | 63.81 | 52.52 | 24.90 | | Total Income | 3022.85 | 4475.53 | 3157.69 | | Cost of goods sold | 2994.23 | 4378.09 | 3205.63 | | OPBDIT | 28.62 | 97.44 | -47.94 | | PAT | 615.58 | -1144.16 | -544.96 | | Gross Block | - | - | - | | Equity capital | 304.85 | 273.35 | 240.35 | | EPS (Rs.) | - | -44.28 | -24.01 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 0.9 | 2.2 | -1.5 | | Net margin (% of OI) | 20.4 | -25.6 | -17.3 |
|
|
Detailed Financials
|
|
|
|
|
